{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:13:24Z","timestamp":1776334404159,"version":"3.51.2"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T00:00:00Z","timestamp":1645228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Genentech, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Amid continued uncertainty about the management of cancer patients during the pandemic, this study sought to obtain real-world data on the use of immune checkpoint inhibitors (ICIs) before COVID-19 diagnosis and its association with severity and survival outcomes in cancer patients who contracted COVID-19.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Cancer patients diagnosed with COVID-19 were identified from a large electronic health record database; those treated with ICIs before COVID-19+ diagnosis were matched in a 1:2 ratio to those not treated with ICIs, using a 2-step matching procedure. A descriptive analysis examined the difference in COVID-19 mortality (30-day and overall) and severity outcomes between the 2 cohorts, and overall survival was compared.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 17\u00a0545 adults \u226518 years with cancer who tested positive for COVID-19 between February 20, 2020, and January 28, 2021, in the US, 228 ICI-treated patients were matched to 456 non-ICI-treated patients, comprising the 2 study cohorts. Clinical characteristics differed significantly between the 2 cohorts before matching, with metastatic disease, lung cancer, a history of smoking, and the presence of pulmonary comorbidities being more common in the ICI-treated cohort; after matching, the 2 cohorts were similar. There were no significant differences between the ICI-treated and non-ICI-treated cohorts for 30-day mortality (12.7% vs. 14.9%, P = .235), overall mortality (22.4% vs. 22.4%, P = 1.000), hospitalization (38.6% vs. 39.0%, P = .912), or emergency department visits (16.7% vs. 14.7%, P = .500). Overall survival was similar between the 2 cohorts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This analysis adds to the clinical evidence base that use of ICIs before SARS-CoV-2 infection does not affect COVID-19 severity or survival outcomes, supporting the continued use of ICIs in cancer patients during the pandemic.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyab083","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T20:09:13Z","timestamp":1641240553000},"page":"236-243","source":"Crossref","is-referenced-by-count":12,"title":["Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3547-4156","authenticated-orcid":false,"given":"Ruoding","family":"Tan","sequence":"first","affiliation":[{"name":"U.S. Medical Affairs, Genentech, Inc., South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Yun","sequence":"additional","affiliation":[{"name":"U.S. Medical Affairs, Genentech, Inc., South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpamas","family":"Seetasith","sequence":"additional","affiliation":[{"name":"U.S. Medical Affairs, Genentech, Inc., South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Sheinson","sequence":"additional","affiliation":[{"name":"U.S. Medical Affairs, Genentech, Inc., South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Walls","sequence":"additional","affiliation":[{"name":"Safety and Risk Management, Product Development, F. Hoffmann-La Roche AG, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Innocent","family":"Ngwa","sequence":"additional","affiliation":[{"name":"Safety and Risk Management, Product Development, F. Hoffmann-La Roche AG, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josina C","family":"Reddy","sequence":"additional","affiliation":[{"name":"Safety and Risk Management, Product Development, F. Hoffmann-La Roche AG, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Personalized Healthcare Data Science, Global Product Development, Genentech, South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew H","family":"Secrest","sequence":"additional","affiliation":[{"name":"Personalized Healthcare Data Science, Global Product Development, Genentech, South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lambert","sequence":"additional","affiliation":[{"name":"Personalized Healthcare Data Science, Global Product Development, Genentech, South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Sarsour","sequence":"additional","affiliation":[{"name":"Personalized Healthcare Data Science, Global Product Development, Genentech, South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,2,19]]},"reference":[{"key":"2022031109004882600_CIT0001","doi-asserted-by":"crossref","first-page":"102041","DOI":"10.1016\/j.ctrv.2020.102041","article-title":"Cancer and COVID-19: unmasking their ties.","volume":"88","author":"Addeo","year":"2020","journal-title":"Cancer Treat Rev."},{"issue":"5","key":"2022031109004882600_CIT0002","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ccell.2020.09.018","article-title":"COVID-19 and cancer: current challenges and perspectives.","volume":"38","author":"Bakouny","year":"2020","journal-title":"Cancer Cell."},{"issue":"5","key":"2022031109004882600_CIT0003","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41591-020-0874-8","article-title":"Caring for patients with cancer in the COVID-19 era.","volume":"26","author":"Van de Haar","year":"2020","journal-title":"Nature Med."},{"issue":"7","key":"2022031109004882600_CIT0004","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","article-title":"COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol."},{"issue":"10241","key":"2022031109004882600_CIT0005","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet."},{"issue":"6","key":"2022031109004882600_CIT0006","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.annonc.2021.02.024","article-title":"Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.","volume":"32","author":"Grivas","year":"2021","journal-title":"Ann Oncol."},{"issue":"33","key":"2022031109004882600_CIT0007","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1200\/JCO.20.01580","article-title":"COVID-19 severity and outcomes in patients with cancer: a matched cohort study.","volume":"38","author":"Brar","year":"2020","journal-title":"J Clin Oncol."},{"key":"2022031109004882600_CIT0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835920971147","article-title":"COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study.","volume":"12","author":"Crolley","year":"2020","journal-title":"Ther Adv Med Oncol."},{"issue":"10241","key":"2022031109004882600_CIT0009","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study.","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet."},{"issue":"10","key":"2022031109004882600_CIT0010","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.annonc.2020.06.007","article-title":"COVID-19 in patients with lung cancer.","volume":"31","author":"Luo","year":"2020","journal-title":"Ann Oncol."},{"issue":"8","key":"2022031109004882600_CIT0011","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1158\/2159-8290.CD-20-0596","article-title":"Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers.","volume":"10","author":"Luo","year":"2020","journal-title":"Cancer Discov."},{"key":"2022031109004882600_CIT0012","first-page":"S1142","article-title":"Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: a CCC19 registry analysis.","volume":"30","author":"Wise-Draper","year":"2020","journal-title":"Ann Oncol."},{"issue":"8","key":"2022031109004882600_CIT0013","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","article-title":"Determinants of COVID-19 disease severity in patients with cancer.","volume":"26","author":"Robilotti","year":"2020","journal-title":"Nat Med."},{"key":"2022031109004882600_CIT0014","first-page":"e001931","article-title":"Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.","volume-title":"J Immunother Cancer.","author":"Rogiers","year":"2021"},{"issue":"7","key":"2022031109004882600_CIT0015","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S1470-2045(20)30309-0","article-title":"Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.","volume":"21","author":"Tian","year":"2020","journal-title":"Lancet Oncol."},{"issue":"7","key":"2022031109004882600_CIT0016","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","article-title":"Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.","volume":"31","author":"Zhang","year":"2020","journal-title":"Ann Oncol."},{"issue":"5","key":"2022031109004882600_CIT0017","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2217\/imt-2020-0067","article-title":"Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.","volume":"12","author":"Bersanelli","year":"2020","journal-title":"Immunotherapy."},{"issue":"23","key":"2022031109004882600_CIT0018","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine Storm.","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med."},{"issue":"13","key":"2022031109004882600_CIT0019","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1084\/jem.20121015","article-title":"Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice.","volume":"209","author":"Frebel","year":"2012","journal-title":"J Exp Med."},{"key":"2022031109004882600_CIT0020","article-title":"Descriptive epidemiology of 16,780 hospitalized COVID-19 patients in the United States.","author":"Chawla","journal-title":"medRxiv Preprint"},{"issue":"4","key":"2022031109004882600_CIT0021","first-page":"188","article-title":"Charlson comorbidity index: ICD-9 update and ICD-10 translation.","volume":"12","author":"Glasheen","year":"2019","journal-title":"Am Health Drug Benefits."},{"key":"2022031109004882600_CIT0022","doi-asserted-by":"crossref","article-title":"TERAVOLT: Thoracic Cancers International COVID-19 Collaboration: impact of cancer therapy and COVID therapy on survival.","author":"Horn","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA111"},{"issue":"1","key":"2022031109004882600_CIT0023","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/0284186X.2020.1837946","article-title":"Association of active oncologic treatment and risk of death in cancer patients with COVID-19: a systematic review and meta-analysis of patient data.","volume":"60","author":"Park","year":"2021","journal-title":"Acta Oncol."},{"key":"2022031109004882600_CIT0024","author":"Centers for Disease Control and Prevention.","year":"2020"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/3\/236\/42828465\/oyab083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/3\/236\/42828465\/oyab083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T09:01:44Z","timestamp":1646989304000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/3\/236\/6532121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,19]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2,19]]},"published-print":{"date-parts":[[2022,3,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyab083","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2022,2,19]]}}}